224 related articles for article (PubMed ID: 16543468)
1. Loss of major histocompatibility class II gene and protein expression in primary mediastinal large B-cell lymphoma is highly coordinated and related to poor patient survival.
Roberts RA; Wright G; Rosenwald AR; Jaramillo MA; Grogan TM; Miller TP; Frutiger Y; Chan WC; Gascoyne RD; Ott G; Muller-Hermelink HK; Staudt LM; Rimsza LM
Blood; 2006 Jul; 108(1):311-8. PubMed ID: 16543468
[TBL] [Abstract][Full Text] [Related]
2. Genomic Alterations in CIITA Are Frequent in Primary Mediastinal Large B Cell Lymphoma and Are Associated with Diminished MHC Class II Expression.
Mottok A; Woolcock B; Chan FC; Tong KM; Chong L; Farinha P; Telenius A; Chavez E; Ramchandani S; Drake M; Boyle M; Ben-Neriah S; Scott DW; Rimsza LM; Siebert R; Gascoyne RD; Steidl C
Cell Rep; 2015 Nov; 13(7):1418-1431. PubMed ID: 26549456
[TBL] [Abstract][Full Text] [Related]
3. Partial plasma cell differentiation as a mechanism of lost major histocompatibility complex class II expression in diffuse large B-cell lymphoma.
Wilkinson ST; Vanpatten KA; Fernandez DR; Brunhoeber P; Garsha KE; Glinsmann-Gibson BJ; Grogan TM; Teruya-Feldstein J; Rimsza LM
Blood; 2012 Feb; 119(6):1459-67. PubMed ID: 22167754
[TBL] [Abstract][Full Text] [Related]
4. FOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas.
Brown PJ; Wong KK; Felce SL; Lyne L; Spearman H; Soilleux EJ; Pedersen LM; Møller MB; Green TM; Gascoyne DM; Banham AH
Leukemia; 2016 Mar; 30(3):605-16. PubMed ID: 26500140
[TBL] [Abstract][Full Text] [Related]
5. Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions.
Rimsza LM; Roberts RA; Campo E; Grogan TM; Bea S; Salaverria I; Zettl A; Rosenwald A; Ott G; Muller-Hermelink HK; Delabie J; Fisher RI; Unger JM; Leblanc M; Staudt LM; Jaffe ES; Gascoyne RD; Chan WC; Weisenburger DD; Greiner T; Braziel RM; Miller TP
Blood; 2006 Feb; 107(3):1101-7. PubMed ID: 16239429
[TBL] [Abstract][Full Text] [Related]
6. Identification of Primary Mediastinal Large B-cell Lymphoma at Nonmediastinal Sites by Gene Expression Profiling.
Yuan J; Wright G; Rosenwald A; Steidl C; Gascoyne RD; Connors JM; Mottok A; Weisenburger DD; Greiner TC; Fu K; Smith L; Rimsza LM; Jaffe ES; Campo E; Martinez A; Delabie J; Braziel RM; Cook JR; Ott G; Vose JM; Staudt LM; Chan WC;
Am J Surg Pathol; 2015 Oct; 39(10):1322-30. PubMed ID: 26135560
[TBL] [Abstract][Full Text] [Related]
7. Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction.
Bea S; Zettl A; Wright G; Salaverria I; Jehn P; Moreno V; Burek C; Ott G; Puig X; Yang L; Lopez-Guillermo A; Chan WC; Greiner TC; Weisenburger DD; Armitage JO; Gascoyne RD; Connors JM; Grogan TM; Braziel R; Fisher RI; Smeland EB; Kvaloy S; Holte H; Delabie J; Simon R; Powell J; Wilson WH; Jaffe ES; Montserrat E; Muller-Hermelink HK; Staudt LM; Campo E; Rosenwald A;
Blood; 2005 Nov; 106(9):3183-90. PubMed ID: 16046532
[TBL] [Abstract][Full Text] [Related]
8. Alterations in CIITA constitute a common mechanism accounting for downregulation of MHC class II expression in diffuse large B-cell lymphoma (DLBCL).
Cycon KA; Rimsza LM; Murphy SP
Exp Hematol; 2009 Feb; 37(2):184-194. PubMed ID: 19081173
[TBL] [Abstract][Full Text] [Related]
9. MHC class II as a therapeutic target in B-cell lymphomas: the CIITA road to paradise?
Diepstra A
Leuk Lymphoma; 2009 Nov; 50(11):1740-1. PubMed ID: 19863170
[No Abstract] [Full Text] [Related]
10. Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project.
Rimsza LM; Roberts RA; Miller TP; Unger JM; LeBlanc M; Braziel RM; Weisenberger DD; Chan WC; Muller-Hermelink HK; Jaffe ES; Gascoyne RD; Campo E; Fuchs DA; Spier CM; Fisher RI; Delabie J; Rosenwald A; Staudt LM; Grogan TM
Blood; 2004 Jun; 103(11):4251-8. PubMed ID: 14976040
[TBL] [Abstract][Full Text] [Related]
11. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers.
Steidl C; Shah SP; Woolcock BW; Rui L; Kawahara M; Farinha P; Johnson NA; Zhao Y; Telenius A; Neriah SB; McPherson A; Meissner B; Okoye UC; Diepstra A; van den Berg A; Sun M; Leung G; Jones SJ; Connors JM; Huntsman DG; Savage KJ; Rimsza LM; Horsman DE; Staudt LM; Steidl U; Marra MA; Gascoyne RD
Nature; 2011 Mar; 471(7338):377-81. PubMed ID: 21368758
[TBL] [Abstract][Full Text] [Related]
12. DLBCL with amplification of JAK2/PD-L2 exhibits PMBCL-like CNA pattern and worse clinical outcome resembling those with MYD88 L265P mutation.
Xue X; Huang W; Qiu T; Guo L; Ying J; Lv N
BMC Cancer; 2020 Aug; 20(1):816. PubMed ID: 32854650
[TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase inhibitors activate CIITA and MHC class II antigen expression in diffuse large B-cell lymphoma.
Cycon KA; Mulvaney K; Rimsza LM; Persky D; Murphy SP
Immunology; 2013 Oct; 140(2):259-72. PubMed ID: 23789844
[TBL] [Abstract][Full Text] [Related]
14. The biology of human lymphoid malignancies revealed by gene expression profiling.
Staudt LM; Dave S
Adv Immunol; 2005; 87():163-208. PubMed ID: 16102574
[TBL] [Abstract][Full Text] [Related]
15. Defective class II transactivator expression in a B lymphoma cell line.
Prod'homme T; Drénou B; De Ruyffelaere C; Barbieri G; Wiszniewski W; Bastard C; Charron D; Alcaide-Loridan C
Leukemia; 2004 Apr; 18(4):832-40. PubMed ID: 14973505
[TBL] [Abstract][Full Text] [Related]
16. [Comparative study between primary mediastinal B-cell lymphoma and non-mediastinal diffuse large B-cell lymphoma by immunoglobulin gene rearrangement and Epstein-Barr virus infection detection].
Zhong DR; Ling Q; Shi XH; Liang ZY; Liu TH
Zhonghua Bing Li Xue Za Zhi; 2012 Jun; 41(6):361-5. PubMed ID: 22932401
[TBL] [Abstract][Full Text] [Related]
17. Genome-wide Screens Identify Lineage- and Tumor-Specific Genes Modulating MHC-I- and MHC-II-Restricted Immunosurveillance of Human Lymphomas.
Dersh D; Phelan JD; Gumina ME; Wang B; Arbuckle JH; Holly J; Kishton RJ; Markowitz TE; Seedhom MO; Fridlyand N; Wright GW; Huang DW; Ceribelli M; Thomas CJ; Lack JB; Restifo NP; Kristie TM; Staudt LM; Yewdell JW
Immunity; 2021 Jan; 54(1):116-131.e10. PubMed ID: 33271120
[TBL] [Abstract][Full Text] [Related]
18. Lack of IKBA coding region mutations in primary mediastinal large B-cell lymphoma and the host response subtype of diffuse large B-cell lymphoma.
Takahashi H; Feuerhake F; Monti S; Kutok JL; Aster JC; Shipp MA
Blood; 2006 Jan; 107(2):844-5. PubMed ID: 16401828
[No Abstract] [Full Text] [Related]
19. Primary mediastinal B-cell lymphoma: hypermutation of the BCL6 gene targets motifs different from those in diffuse large B-cell and follicular lymphomas.
Malpeli G; Barbi S; Moore PS; Scardoni M; Chilosi M; Scarpa A; Menestrina F
Haematologica; 2004 Sep; 89(9):1091-9. PubMed ID: 15377470
[TBL] [Abstract][Full Text] [Related]
20. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma.
Rosenwald A; Wright G; Leroy K; Yu X; Gaulard P; Gascoyne RD; Chan WC; Zhao T; Haioun C; Greiner TC; Weisenburger DD; Lynch JC; Vose J; Armitage JO; Smeland EB; Kvaloy S; Holte H; Delabie J; Campo E; Montserrat E; Lopez-Guillermo A; Ott G; Muller-Hermelink HK; Connors JM; Braziel R; Grogan TM; Fisher RI; Miller TP; LeBlanc M; Chiorazzi M; Zhao H; Yang L; Powell J; Wilson WH; Jaffe ES; Simon R; Klausner RD; Staudt LM
J Exp Med; 2003 Sep; 198(6):851-62. PubMed ID: 12975453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
